drugset / Trial / NCT00002280
A Study of ddI in Children With AIDS Who Have Not Had Success With Zidovudine
Completed
Bristol-Myers Squibb
Open-labelTreatment
Summary
The purpose of this study is to make didanosine (ddI) available to children with AIDS who are clinically deteriorating on zidovudine (AZT) or intolerant to AZT and cannot enter the Phase II ddI programs due to protocol exclusion or geographic location.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- 1994-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Didanosine | Small molecule | — | — |